Johnson & Johnson (JNJ)
Kapitalizacja
547.64 mld USD
C/Z (P/E)
26,39
Dywidenda
2,25%
Wolumen
5.8 mln
Zmiana 52 tyg.
+46,44%
Wykres kursu JNJ
Obecny kurs: 227,50 USD (77% zakresu)
Kurs vs średnie kroczące
Wskaźniki wyceny
| C/Z (P/E trailing) | 26,39 |
| C/Z prognozowany (forward) | 17,90 |
| C/WK (P/B) | 6,72 |
| Zysk na akcję (EPS TTM) | 8,62 USD |
| Kapitalizacja rynkowa | 547.64 mld USD |
Dane handlowe
| Ostatnia cena | 227,50 USD |
| Zmiana dzienna | -3,15 (-1,37%) |
| Wolumen obrotu | 5.8 mln |
| Zmiana roczna (52 tyg.) | +46,44% |
| Giełda | NYSE |
| Waluta | USD |
| Sektor | Ochrona zdrowia |
| Branża | Drug Manufacturers - General |
Dywidenda
Stopa dywidendy
2,25%
Roczna dywidenda
5,20 USD
na akcję
Podatki w Polsce
| Podatek od zysków (PIT-38) | 19% |
| WHT od dywidendy (USA) | 15,0% |
| Dopłata w PL do 19% | 4,0% |
| Łączny podatek od dywidendy | 19,0% |
| Stopa dywidendy netto | 1,83% |
Gdzie kupić
| Broker | Dostęp | IKE/IKZE |
|---|---|---|
| XTB | Tak (0% do 100k EUR/msc) | IKE |
| Interactive Brokers | Tak | Nie |
| mBank eMakler | Tak | IKE + IKZE |
| BOSSA | Tak | IKE + IKZE |
O spółce
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Dodaj JNJ do portfela
Monitoruj kurs, dywidendy i wskaźniki na żywo. Import transakcji z XTB, mBank, Interactive Brokers.